Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -38.65% is 49% above its 5-year average of -76.19%, near the high end of its 5-year range (-105.31%–-38.65%).
36.11% above its 12-month average of -60.49%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -5.68%.
RETURN ON ASSETS (ROA)
-38.65%
RETURN ON ASSETS (ROA) AVG TTM
-60.49%
RETURN ON ASSETS (ROA) AVG 3Y
-64.82%
RETURN ON ASSETS (ROA) AVG 5Y
-76.19%
RETURN ON ASSETS (ROA) AVG 10Y
-62.04%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+36.11%
CURRENT VS 3Y AVG
+40.37%
CURRENT VS 5Y AVG
+49.27%
CURRENT VS 10Y AVG
+37.70%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-19.88%
vs the sector median at left
UroGen Pharma Ltd.
Market Cap
$2.01B
Return on Assets (ROA)
-38.65%
TTM Avg
-60.49%
3Y Avg
-64.82%
5Y Avg
-76.19%
Market Cap
$2.01B
Return on Assets (ROA)
-68.96%
TTM Avg
16.60%
3Y Avg
-13.89%
5Y Avg
-23.58%
Market Cap
$2.01B
Return on Assets (ROA)
39.65%
TTM Avg
19.63%
3Y Avg
0.51%
5Y Avg
-8.90%
Market Cap
$2.03B
Return on Assets (ROA)
10.98%
TTM Avg
8.41%
3Y Avg
7.65%
5Y Avg
11.22%
Market Cap
$1.98B
Return on Assets (ROA)
-3.14%
TTM Avg
-22.75%
3Y Avg
-10.43%
5Y Avg
-6.58%
Market Cap
$2.05B
Return on Assets (ROA)
4.82%
TTM Avg
2.89%
3Y Avg
-0.31%
5Y Avg
-0.49%
Market Cap
$2.06B
Return on Assets (ROA)
-35.27%
TTM Avg
-37.23%
3Y Avg
-38.20%
5Y Avg
-46.02%
Market Cap
$1.98B
Return on Assets (ROA)
14.58%
TTM Avg
11.33%
3Y Avg
2.89%
5Y Avg
-3.84%
Market Cap
$2.07B
Return on Assets (ROA)
-38.42%
TTM Avg
-32.16%
3Y Avg
-31.63%
5Y Avg
-27.96%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.01B | -38.65% | -60.49% | -64.82% | -76.19% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.01B | -68.96% | 16.60% | -13.89% | -23.58% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.01B | 39.65% | 19.63% | 0.51% | -8.90% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 10.98% | 8.41% | 7.65% | 11.22% |
| Fortrea Holdings Inc. (FTRE)vs › | $1.98B | -3.14% | -22.75% | -10.43% | -6.58% |
| Vericel Corporation (VCEL)vs › | $2.05B | 4.82% | 2.89% | -0.31% | -0.49% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | -35.27% | -37.23% | -38.20% | -46.02% |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.98B | 14.58% | 11.33% | 2.89% | -3.84% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | -38.42% | -32.16% | -31.63% | -27.96% |
| Alvotech (ALVO)vs › | $2.07B | -11.31% | -8.55% | -34.29% | -31.66% |
ROA
-38.6%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -76.57% |
| 2024-12-31 | -44.41% |
| 2023-12-31 | -57.34% |
| 2022-12-31 | -80.95% |
| 2021-12-31 | -92.55% |
| 2020-12-31 | -105.31% |
| 2019-12-31 | -51.95% |
| 2018-12-31 | -73.06% |
| 2017-12-31 | -26.47% |
| 2016-12-31 | -8.42% |
| 2015-12-31 | -65.44% |
| 2014-12-31 | -104.54% |
| 2013-12-31 | -102.51% |
